Biopharma product and portfolio strategy firm Prescient Healthcare Group has added three existing employees to its Board of Directors: Erica Carlisle, Paul Harney and Swati Anand Kkatyal.
Prescient is a pharma services firm specializing in dynamic decision support and product and portfolio strategy. The business has operations in ten cities across three continents, and its team of nearly 500 execs partners with global biopharmaceutical companies.
Carlisle is the Head of the Global Commercial Practice, having joined last year with two decades of experience in healthcare consulting and biotechnology, most recently as VP at Zymergen, and earlier with Boston Consulting Group, as North America topic lead for biopharma launches. She is based in the San Mateo office, from where she will focus on uncovering and understanding the drivers of decision making. Harney, who is the company's Chief Commercial Officer, joined the Jersey City office in 2018, having previously spent more than 25 years in leadership roles at consultancies including Deloitte and Quintiles.
Swati currently serves as Head of the Global Data, Analytics and Technology Practice, after joining the London office in 2008, then moving to India in 2010 to establish the New Delhi office. During her time with the company, she was also responsible for operationalizing the InflexionRx Software Development and Prescient Data & Analytics teams in India.
CEO Debasish Talukdar comments: 'With Erica, Paul and Swati on the Board, we are strengthened by their expertise and experience serving the pharmaceutical industry. They will bring diverse perspectives to add depth and breadth to our Board and accurately reflect the global nature of our business across the US, EU, UK and Asia.'
Web site: www.prescienthg.com .
All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.
Register (free) for Daily Research News
REGISTER FOR NEWS EMAILS
To receive (free) news headlines by email, please register online